Sector
PharmaceuticalsOpen
₹2,545Prev. Close
₹2,545.7Turnover(Lac.)
₹2,281.6Day's High
₹2,594.9Day's Low
₹2,52552 Week's High
₹3,48552 Week's Low
₹2,160.15Book Value
₹290.22Face Value
₹2Mkt Cap (₹ Cr.)
32,329.75P/E
35.22EPS
73.4Divi. Yield
1.09Ajanta Pharma reported a strong EBITDA margin of 25% in the quarter.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 25.27 | 25.27 | 17.17 | 17.39 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 3,388.3 | 3,221.18 | 3,152.01 | 2,867.59 |
Net Worth | 3,413.57 | 3,246.45 | 3,169.18 | 2,884.98 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 3,140.64 | 2,718.59 | 2,196.42 | 1,825.35 |
yoy growth (%) | 15.52 | 23.77 | 20.32 | 1.16 |
Raw materials | -832.56 | -730.08 | -663.97 | -399.29 |
As % of sales | 26.5 | 26.85 | 30.22 | 21.87 |
Employee costs | -585.87 | -498.11 | -437.82 | -342.89 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 900.54 | 902.09 | 616.59 | 562.44 |
Depreciation | -120.96 | -111.49 | -91.29 | -57.14 |
Tax paid | -180.68 | -226.45 | -171.54 | -134.92 |
Working capital | 278.87 | 306.22 | 272.08 | 231.17 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.52 | 23.77 | 20.32 | 1.16 |
Op profit growth | -2.83 | 72.09 | -2.56 | -13.8 |
EBIT growth | 0.07 | 45.27 | 11.19 | -12.34 |
Net profit growth | 6.54 | 53.16 | 3.18 | -14.46 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 4,648.1 | 4,208.71 | 3,742.64 | 3,340.99 | 2,889.69 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 4,648.1 | 4,208.71 | 3,742.64 | 3,340.99 | 2,889.69 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 94.5 | 84.6 | 98.64 | 115.68 | 25.98 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.6 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.1 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,164 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Mannalal B Agrawal
Vice Chairman
Madhusudan B Agrawal
Managing Director
Yogesh Agrawal
Vice President & CS
Gaurang Shah
Joint Managing Director
Rajesh M Agrawal
Independent Director
David Rasquinha
Independent Director
Medha Joshi
Independent Director
Simi Thapar
Independent Director
Rajesh Shashikant Dalal
Ajanta House,
Charkop Kandivli (W),
Maharashtra - 400067
Tel: 91-22-66061000/1204/1203
Website: http://www.ajantapharma.com
Email: info@ajantapharma.com; investorgrievance@ajantapha
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Ajanta Pharma Limited is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa. The Company is in...
Read More
Reports by Ajanta Pharma Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.